Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study

Maturitas. 2009 Oct 20;64(2):136-8. doi: 10.1016/j.maturitas.2009.08.013. Epub 2009 Sep 25.

Abstract

Hormone therapy (HT) increases venous thromboembolism (VTE) risk among postmenopausal women. Data on the influence of steroids receptors polymorphisms on this association remain scarce. Since progesterone receptor (hPR) is expressed in human veins and specific progestogens increase VTE risk, we investigated the impact of the functional +331G/A hPR polymorphism on the association of VTE with HT. Using the data of the ESTHER study, we showed that ORs for VTE in current users of progesterone or progestins were not significantly different by hPR+331G/A genotype status. hPR polymorphism appears not to have a significant effect on VTE risk related to HT.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Case-Control Studies
  • Estrogen Replacement Therapy / adverse effects*
  • Estrogens / adverse effects
  • Female
  • Humans
  • Middle Aged
  • Odds Ratio
  • Polymorphism, Genetic*
  • Postmenopause
  • Progesterone / adverse effects*
  • Progestins / adverse effects*
  • Receptors, Progesterone / genetics*
  • Risk Factors
  • Venous Thromboembolism / etiology*

Substances

  • Estrogens
  • Progestins
  • Receptors, Progesterone
  • Progesterone